Abstract
Antiretroviral therapy has reduced HIV-related morbidity and mortality substantially. WHO recommends the use of Nevirapine or Efavirenz as first line combined with two from nucleoside reverse transcriptase inhibitors. In this study the immunological outcomes of Neverapin versus Efafrenz based ART was assessed. Medical records of patients were retrieved and important variables were captured to standard questionnaire. Medical records of 120 patients from NVP-based regimen and 60 patients from EFV groups were revised. The CD4 cell count at the start of HAART ranged from 3-2003 cell/ml with an inter quartile range (IQR) of 231-317 cell/ml among NVP group. And among patients taking EFV based ART regimen, baseline CD4 count ranged 13-2095 cell/ml with an IQR range of 250-345 cell/ml. After six months of HAART, the CD4 cell count of NVP based regimen range from 71-2300 c/ml with IQR of 458-612 c/ml, and mean CD4 cell count difference of 215, 95% CI (175.414-245.613). From EFV based group, CD4 count ranged from 65-2100 c/ml with IQR of 435-605 c/ml, and the mean CD4 cell count difference of 205, 95% CI (155.404-235.623). The immunological recovery was found to be comparable among the two groups. Advanced clinical stage of the disease, severe immune suppression, presence of anemia, presence of chronic diarrhea , poor weight gain during first six months of ART were adversely affected the trends of CD4 recovery. This research report demonstrated that immunological outcomes were comparable among patient taking NVP vs EFV based ART regimen. Key words: Immunologic outcomes, HIV/AIDS; HAART/ART, nevirapine (NVP), efavirenz (EFV).
Highlights
Antiretroviral therapy (ART) reduces human immune-virus (HIV)-related mortality and morbidity substantially among HIV infected patients
This study focuses on assessing immunologic outcomes of the two first lines (NVP versus EFV) nonnucleoside reverse transcriptase inhibitors (NNRTI) which could contribute some inputs for the scarce and conflicting data so far reported
A comparative cross sectional study was conducted by evaluating ART documents of children infected with HIV who were taking ART at Pediatric Infectious Disease clinic (PIDC), Black Lion Hospital (BLH)
Summary
Antiretroviral therapy (ART) reduces HIV-related mortality and morbidity substantially among HIV infected patients. If HAART is not started timely, a third of children infected prenatally will not survive to their first birthday, and more than half will succumb to death by their second birthday (Abebe, 2017). The advent of highly active antiretroviral therapy (ART) has brought a paradigm shift in the survival of HIV infected patient. The standard therapy consists of two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
